Patient characteristics and treatment delivery
| Pat. . | UPN . | Sex . | Age, y . | Disease . | Conditioning . | Stem-cell product . | SD, CD3+, ×108/kg . | aGVHD, grade . | aGVHD, site . | cGVHD, grade . | Relapse . | Sample availability for FOXP3 analysis . | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Before . | Don . | SD . | d30 . | d60 . | d90 . | |||||||||||||||||||
| CD34+, ×106/kg . | CD3+, ×104/kg . | P . | F . | P . | F . | P . | F . | P . | F . | P . | F . | P . | F . | |||||||||||
| 1 | 429 | m | 58 | MDS/AML | Flu/Bu | 3.8 | 0.25 | 0.7 | 0 | NA | Limited | No | x | x | x | x | x | x | ||||||
| 2 | 415 | m | 61 | AML | Flu/Bu | 3.4 | 0.20 | 1.1 | 0 | NA | 0 | No | x | x | x | x | x | x | x | |||||
| 3 | 440 | f | 68 | MDS/AML | Flu/Cy | 3.5 | 0.10 | 0.9 | 1 | Skin | 0 | No | x | x | x | x | x | x | x | x | ||||
| 4 | 397 | m | 73 | MDS/AML | Flu/Mel | 6.9 | 0.25 | 1.0 | 0 | NA | 0 | Yes | x | x | x | x | x | x | x | x | ||||
| 5 | 363 | m | 65 | MDS | Flu/Mel | 6.1 | 5.00 | 0.7 | 1 | Skin | Limited | No | x | x | x | x | x | x | x | x | x | x | x | |
| 6 | 418 | m | 71 | ALL | Flu/Cy | 5.9 | 0.10 | 1.0 | 2 | Skin, gut | Limited | No | x | x | x | x | x | x | x | x | ||||
| 7 | 378 | m | 61 | MDS/AML | Flu/Mel | 7.3 | 0.27 | 1.5 | 2 | Skin | Extensive | No | x | x | x | x | x | x | x | x | x | x | ||
| 8 | 345 | m | 66 | MDS | Flu/Cy | 3.8 | 5.00 | 1.4 | 2 | Skin | Limited | No | x | x | x | x | x | x | x | |||||
| 9 | 382 | f | 72 | SLL/CLL | Flu/Mel | 4.9 | 0.17 | 1.4 | 2 | Gut | 0 | No | x | x | x | x | x | x | x | x | ||||
| 10 | 385 | f | 64 | MDS | Flu/Mel | 4.5 | 0.30 | 0.5 | 2 | Skin, liver | Limited | Yes | x | x | x | x | x | x | x | x | ||||
| 11 | 301 | m | 58 | CMMoL | Flu/Cy | 6.7 | 5.00 | 1.1 | 0 | NA | 0 | Yes | x | x | x | x | x | x | x | x | x | x | x | x |
| 12 | 307 | m | 68 | MDS/AML | Flu/Cy | 3.6 | 5.00 | 0.8 | 1 | Skin | 0 | Yes | x | x | x | x | x | x | x | x | ||||
| 13 | 413 | f | 59 | MDS/AML | Flu/Bu | 4.3 | 0.18 | 0.2 | 0 | NA | Limited | Yes | x | x | x | x | ||||||||
| 14 | 427 | m | 52 | MDS | Flu/Bu | 4.1 | 0.15 | 0.7 | 4 | Gut | 0 | No | x | x | x | x | ||||||||
| 15 | 443 | m | 69 | MDS/AML | Flu/Bu | 4.5 | 0.10 | 1.2 | 0 | NA | 0 | Yes | x | x | x | x | x | x | x | x | ||||
| 16 | 465 | f | 55 | MCL | Flu/Cy | 4.9 | 0.30 | 1.0 | 0 | NA | 0 | No | x | x | x | x | x | x | x | x | x | |||
| Pat. . | UPN . | Sex . | Age, y . | Disease . | Conditioning . | Stem-cell product . | SD, CD3+, ×108/kg . | aGVHD, grade . | aGVHD, site . | cGVHD, grade . | Relapse . | Sample availability for FOXP3 analysis . | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Before . | Don . | SD . | d30 . | d60 . | d90 . | |||||||||||||||||||
| CD34+, ×106/kg . | CD3+, ×104/kg . | P . | F . | P . | F . | P . | F . | P . | F . | P . | F . | P . | F . | |||||||||||
| 1 | 429 | m | 58 | MDS/AML | Flu/Bu | 3.8 | 0.25 | 0.7 | 0 | NA | Limited | No | x | x | x | x | x | x | ||||||
| 2 | 415 | m | 61 | AML | Flu/Bu | 3.4 | 0.20 | 1.1 | 0 | NA | 0 | No | x | x | x | x | x | x | x | |||||
| 3 | 440 | f | 68 | MDS/AML | Flu/Cy | 3.5 | 0.10 | 0.9 | 1 | Skin | 0 | No | x | x | x | x | x | x | x | x | ||||
| 4 | 397 | m | 73 | MDS/AML | Flu/Mel | 6.9 | 0.25 | 1.0 | 0 | NA | 0 | Yes | x | x | x | x | x | x | x | x | ||||
| 5 | 363 | m | 65 | MDS | Flu/Mel | 6.1 | 5.00 | 0.7 | 1 | Skin | Limited | No | x | x | x | x | x | x | x | x | x | x | x | |
| 6 | 418 | m | 71 | ALL | Flu/Cy | 5.9 | 0.10 | 1.0 | 2 | Skin, gut | Limited | No | x | x | x | x | x | x | x | x | ||||
| 7 | 378 | m | 61 | MDS/AML | Flu/Mel | 7.3 | 0.27 | 1.5 | 2 | Skin | Extensive | No | x | x | x | x | x | x | x | x | x | x | ||
| 8 | 345 | m | 66 | MDS | Flu/Cy | 3.8 | 5.00 | 1.4 | 2 | Skin | Limited | No | x | x | x | x | x | x | x | |||||
| 9 | 382 | f | 72 | SLL/CLL | Flu/Mel | 4.9 | 0.17 | 1.4 | 2 | Gut | 0 | No | x | x | x | x | x | x | x | x | ||||
| 10 | 385 | f | 64 | MDS | Flu/Mel | 4.5 | 0.30 | 0.5 | 2 | Skin, liver | Limited | Yes | x | x | x | x | x | x | x | x | ||||
| 11 | 301 | m | 58 | CMMoL | Flu/Cy | 6.7 | 5.00 | 1.1 | 0 | NA | 0 | Yes | x | x | x | x | x | x | x | x | x | x | x | x |
| 12 | 307 | m | 68 | MDS/AML | Flu/Cy | 3.6 | 5.00 | 0.8 | 1 | Skin | 0 | Yes | x | x | x | x | x | x | x | x | ||||
| 13 | 413 | f | 59 | MDS/AML | Flu/Bu | 4.3 | 0.18 | 0.2 | 0 | NA | Limited | Yes | x | x | x | x | ||||||||
| 14 | 427 | m | 52 | MDS | Flu/Bu | 4.1 | 0.15 | 0.7 | 4 | Gut | 0 | No | x | x | x | x | ||||||||
| 15 | 443 | m | 69 | MDS/AML | Flu/Bu | 4.5 | 0.10 | 1.2 | 0 | NA | 0 | Yes | x | x | x | x | x | x | x | x | ||||
| 16 | 465 | f | 55 | MCL | Flu/Cy | 4.9 | 0.30 | 1.0 | 0 | NA | 0 | No | x | x | x | x | x | x | x | x | x | |||
Blood samples (PBMCs, apheresis products, processed lymphocyte products) were studied in 16 patients (before and after transplantation [day 30 to day 90]), 13 of their donors, and 10 selectively CD25-depleted lymphocyte products (SD) based on their availability by PCR (P) and/or flow cytometry (F). As far as DLIs were given or patients received CD25 antibodies for GvHD treatment only samples taken before these events were studied.
UPN indicates unique patient number; aGVHD, acute graft-versus-host disease; cGVHD, chronic graft-versus-host disease; MDS, myelodysplastic syndrome; AML, acute myeloid leukemia; Flu, fludarabine; Bu, busulfan; NA, not assessable; Cy, cyclophosphamide; Mel, melphalan; ALL, acute lymphoblastic leukemia; SLL, small lymphocytic lymphoma; CLL, chronic lymphocytic leukemia; CMMol, chronic myelo-monocytic leukemia; MCL, mantle-cell lymphoma; X, sample available for analysis.